Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-06
2007-03-06
Stucker, Jeffrey (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S369000, C435S320100, C435S235100
Reexamination Certificate
active
09663458
ABSTRACT:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
REFERENCES:
patent: 5436131 (1995-07-01), Condra et al.
patent: 5766842 (1998-06-01), Melnick et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 2003/0108857 (2003-06-01), Parkin et al.
patent: 2004/0106106 (2004-06-01), Parkin et al.
patent: WO99/67427 (1999-06-01), None
patent: PCT/US00/17178 (2000-12-01), None
patent: WO00/78996 (2000-12-01), None
patent: PCT/US01/28754 (2002-03-01), None
patent: WO02/22076 (2002-03-01), None
patent: WO02/068618 (2002-09-01), None
patent: WO02/099387 (2002-12-01), None
patent: PCT/US02/18684 (2003-01-01), None
patent: WO03/070700 (2003-08-01), None
patent: WO04/003512 (2004-01-01), None
patent: WO04/003514 (2004-01-01), None
patent: PCT/US03/21335 (2004-05-01), None
patent: PCT/US03/21355 (2004-05-01), None
patent: PCT/US03/21023 (2004-07-01), None
patent: PCT/US03/04362 (2004-12-01), None
Patick et al. Antimicrobial Agents and Chemotherapy. 1998; 42 (10): 2637-2644.
Hazuda et al. Science. Jan. 2000; 287: 646-650.
Craig et al. AIDS. 1998; 12: 1611-1618.
Young, B. et al., Resistance Mutations in Protease and Reverse Transcriptase Genes of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure,Journal of Infectious Diseases, vol. 178, No. 5, pp. 1497-1501 (Nov. 1998).
Hertogs et al., A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Drugs.Antimicrobial Agents and Chemotherapy, vol. 42, No. 2, pp. 269-276 (Feb. 1998).
Ziermann et al., “A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes in Vitro Hypersensitivity to Amprenavir,” (2000), Journal of Virology, 74:4414-4419.
Dreyer GB, et al.“A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically”Biochemistry(1993) 32:937-947.
J. Eron, et al., Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors,5th Conference on Retroviruses and Opportunistic Infections: (1995) 6.
Hill, A. et al. (1998) “Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar,” Int. Conf.AIDS12:812, (Abstract No. 6).
E. E. Kim, (1995) “Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme,” J. AM. Chem. Soc., 117: 1181-1182.
Lambert DM, et al. (1992) “Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells”Anit Microb Agents Chem36:982-98.
Brendan A. Larder, et al., (1995) “Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy,”Science, 269; 696-699.
Janis K. Lazdins, et al., (1997) “In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study wits Other Relevant HIV Protease Inhibitors,”J Infec. Dis., 175: 1063-1070.
David J. Livingston, et al., (1995) “Weak Binding of VX-478 tc Human Plasma Proteins and Implications for Anti-Humar Immunodeficiency Virus Therapy,”J Infec. Dis.,172:1. 238-124.
Bhuvaneshwari Mahalingam, et al., (1999) “Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease,”Biochem., 263: 1-9.
Miller M, et al. (1989) Structure of Complex of Synthetic HIV-1j Protease with a SubstrateBased Inhibitor at 2.3 A Resolution,Science246: 1149-1152.
Mohri H, et al. (1993) “Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients,”PNAS90:25-29.
Robert L. Murphy, et al., (1999) “Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection”J. Infec. Dis., 179: 808-81 E.
Najera I, et al. (1994) “Natural Occurrence of Drug ResistancE Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates,”Aids Res Hum Retroviruses10:1479-1488.
Najera l, et al. (1995) “pol Gene Quasispecies of Humar Immunodeficiency Virus: Mutations Associated with Drug ResistancE in Virus From Patients Undergoing No Drug Therapy,”J Virol69:23-31.
Sarah Palmer, et al., (1999) “Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compunds in Current Clinical Development,”AIDS, 13:661-667.
Neil T. Parkin, et al., (1999) “Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy,”J Infec. Dis., 180: 865-870.
Judith A. Partaledis, et al., (1995) “In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease,”Journal of Virology. 69: 5228-5235.
Petit SC, et al. (1993) “The Specificity of the HIV-1 Protease”Drug Discov Des1:69-83.
Roberts NA, et al. (1990) “Rational Design of Peptide-Based HIV Proteinase”Science248:358361.
Roberts, N. A., (1995) “Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors,”AIDS.9(supp 2) S27-S32.
Brian M. Sadler, et al., (1999) “Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following oral Administration of Single Doses to HIV-Infected Adults,”Antimicrobial Agents and Chemtherapy, 43: 1686-1692.
Sarkar G. and Sommer SS., (1990) “The“Megaprimer”Method of Site-Directed Mutagenesis,”Bio Tech8(4):404-407.
Mary L. Smidt, et al., (1996) “A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside the Active Site, Confers Resistance to the Hydroxyethylurea Inhibitor SC-55389A,”Antimicrobial Agents and Chemotherapy, 41: 515-522.
M. H. St. Clair, et al., (1996) “In Vitro Antiviral Activity of 141 W94 (VX-478) in Combination with Other Antiretroviral Agents,”Antiviral Research29: 53-56.
H. Tian, et al., (1998) “Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity, ” 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30.
Tisdale, M. et al. (1998): “Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy, ”Int. Conf AIDS12:583 (Abstract No. 32312).
Simon P. Tucker, et al., (1998) “Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro,”Antimicrobial Agents and Chemotherapy, 42: 478-480.
Craig et al., 1998 “HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy”,AIDS, 12: 1611-1618.
Carrillo et al., (1998), “In Vitro Selection and Characterization of Human Immunodefciency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor,”Journal of Virology, 72(9): 7532-41.
Condra et al., (1996), “Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor,”Journal of Virology, 70(12): 8270-76.
Genbank Ac
Parkin Neil T.
Ziermann Rainer A.
Jones Day
Monogram Biosciences, Inc.
Peng Bo
Stucker Jeffrey
LandOfFree
Means and methods for monitoring protease inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means and methods for monitoring protease inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means and methods for monitoring protease inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785098